BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schneider SA, Obeso JA. Clinical and pathological features of Parkinson's disease. Curr Top Behav Neurosci 2015;22:205-20. [PMID: 24850081 DOI: 10.1007/7854_2014_317] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 7.4] [Reference Citation Analysis]
Number Citing Articles
1 Calap-Quintana P, González-Fernández J, Sebastiá-Ortega N, Llorens JV, Moltó MD. Drosophila melanogaster Models of Metal-Related Human Diseases and Metal Toxicity. Int J Mol Sci 2017;18:E1456. [PMID: 28684721 DOI: 10.3390/ijms18071456] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
2 Arab HH, Safar MM, Shahin NN. Targeting ROS-Dependent AKT/GSK-3β/NF-κB and DJ-1/Nrf2 Pathways by Dapagliflozin Attenuates Neuronal Injury and Motor Dysfunction in Rotenone-Induced Parkinson's Disease Rat Model. ACS Chem Neurosci 2021;12:689-703. [PMID: 33543924 DOI: 10.1021/acschemneuro.0c00722] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
3 Chi J, Xie Q, Jia J, Liu X, Sun J, Deng Y, Yi L. Integrated Analysis and Identification of Novel Biomarkers in Parkinson's Disease. Front Aging Neurosci 2018;10:178. [PMID: 29967579 DOI: 10.3389/fnagi.2018.00178] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
4 Engel PA. Is age-related failure of metabolic reprogramming a principal mediator in idiopathic Parkinson's disease? Implications for treatment and inverse cancer risk. Med Hypotheses 2016;93:154-60. [PMID: 27372878 DOI: 10.1016/j.mehy.2016.05.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
5 Schrag A, Taddei RN. Depression and Anxiety in Parkinson's Disease. Nonmotor Parkinson's: The Hidden Face - The Many Hidden Faces. Elsevier; 2017. pp. 623-55. [DOI: 10.1016/bs.irn.2017.05.024] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 8.6] [Reference Citation Analysis]
6 García AM, Salado IG, Perez DI, Brea J, Morales-García JA, González-García A, Cadavid MI, Loza MI, Luque FJ, Perez-Castillo A, Martinez A, Gil C. Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease. Future Med Chem 2017;9:731-48. [PMID: 28485668 DOI: 10.4155/fmc-2017-0005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
7 Outeiro TF, Heutink P, Bezard E, Cenci AM. From iPS Cells to Rodents and Nonhuman Primates: Filling Gaps in Modeling Parkinson's Disease. Mov Disord 2021;36:832-41. [PMID: 33200446 DOI: 10.1002/mds.28387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Peihua L, Jianqin W. Clinical Effects of Piribedil in Adjuvant Treatment of Parkinson's Disease: A Meta-Analysis. Open Med (Wars) 2018;13:270-7. [PMID: 30019007 DOI: 10.1515/med-2018-0041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Fričová D, Korchak JA, Zubair AC. Challenges and translational considerations of mesenchymal stem/stromal cell therapy for Parkinson's disease. NPJ Regen Med 2020;5:20. [PMID: 33298940 DOI: 10.1038/s41536-020-00106-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
10 Cenci MA, Crossman AR. Animal models of l-dopa-induced dyskinesia in Parkinson's disease. Mov Disord 2018;33:889-99. [PMID: 29488257 DOI: 10.1002/mds.27337] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
11 Pérez-Roca L, Prada-Dacasa P, Segú-Vergés C, Gámez-Valero A, Serrano-Muñoz MA, Santos C, Beyer K. Glucocerebrosidase regulators SCARB2 and TFEB are up-regulated in Lewy body disease brain. Neurosci Lett 2019;706:164-8. [PMID: 31116970 DOI: 10.1016/j.neulet.2019.05.034] [Reference Citation Analysis]
12 Fieblinger T. Striatal Control of Movement: A Role for New Neuronal (Sub-) Populations? Front Hum Neurosci 2021;15:697284. [PMID: 34354577 DOI: 10.3389/fnhum.2021.697284] [Reference Citation Analysis]
13 Marogianni C, Sokratous M, Dardiotis E, Hadjigeorgiou GM, Bogdanos D, Xiromerisiou G. Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease. Int J Mol Sci 2020;21:E8421. [PMID: 33182554 DOI: 10.3390/ijms21228421] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
14 Maatouk L, Yi C, Carrillo-de Sauvage MA, Compagnion AC, Hunot S, Ezan P, Hirsch EC, Koulakoff A, Pfrieger FW, Tronche F, Leybaert L, Giaume C, Vyas S. Glucocorticoid receptor in astrocytes regulates midbrain dopamine neurodegeneration through connexin hemichannel activity. Cell Death Differ 2019;26:580-96. [PMID: 30006609 DOI: 10.1038/s41418-018-0150-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
15 Waløen K, Kleppe R, Martinez A, Haavik J. Tyrosine and tryptophan hydroxylases as therapeutic targets in human disease. Expert Opin Ther Targets 2017;21:167-80. [PMID: 27973928 DOI: 10.1080/14728222.2017.1272581] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
16 Langley MR, Ghaisas S, Palanisamy BN, Ay M, Jin H, Anantharam V, Kanthasamy A, Kanthasamy AG. Characterization of nonmotor behavioral impairments and their neurochemical mechanisms in the MitoPark mouse model of progressive neurodegeneration in Parkinson's disease. Exp Neurol 2021;341:113716. [PMID: 33839143 DOI: 10.1016/j.expneurol.2021.113716] [Reference Citation Analysis]
17 Agliardi C, Guerini FR, Zanzottera M, Riboldazzi G, Zangaglia R, Sturchio A, Casali C, Di Lorenzo C, Minafra B, Nemni R, Clerici M. SNAP25 Gene Polymorphisms Protect Against Parkinson's Disease and Modulate Disease Severity in Patients. Mol Neurobiol 2019;56:4455-63. [PMID: 30334187 DOI: 10.1007/s12035-018-1386-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
18 Joshi N, Singh S. Updates on immunity and inflammation in Parkinson disease pathology. Journal of Neuroscience Research 2018;96:379-90. [DOI: 10.1002/jnr.24185] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
19 Muñoz-ospina B, Alvarez-garcia D, Clavijo-moran HJC, Valderrama-chaparro JA, García-peña M, Herrán CA, Urcuqui CC, Navarro-cadavid A, Orozco J. Machine Learning Classifiers to Evaluate Data From Gait Analysis With Depth Cameras in Patients With Parkinson’s Disease. Front Hum Neurosci 2022;16:826376. [DOI: 10.3389/fnhum.2022.826376] [Reference Citation Analysis]
20 Bezem MT, Johannessen FG, Jung-Kc K, Gundersen ET, Jorge-Finnigan A, Ying M, Betbeder D, Herfindal L, Martinez A. Stabilization of Human Tyrosine Hydroxylase in Maltodextrin Nanoparticles for Delivery to Neuronal Cells and Tissue. Bioconjug Chem 2018;29:493-502. [PMID: 29299922 DOI: 10.1021/acs.bioconjchem.7b00807] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Zhu J, Zhong M, Yan J, Jiang X, Wu Z, Pan Y, Shen B, Zhang L, Dong J, Zhang L. Nonmotor Symptoms Affect Sleep Quality in Early-Stage Parkinson's Disease Patients With or Without Cognitive Dysfunction. Front Neurol 2020;11:292. [PMID: 32373056 DOI: 10.3389/fneur.2020.00292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Alieva A, Rudenok M, Filatova E, Karabanov A, Doronina O, Doronina K, Kolacheva A, Ugrumov M, Illarioshkin S, Slominsky P, Shadrina M. VCP expression decrease as a biomarker of preclinical and early clinical stages of Parkinson's disease. Sci Rep 2020;10:827. [PMID: 31964996 DOI: 10.1038/s41598-020-57938-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Lattari E, Pereira-Junior PP, Neto GA, Lamego MK, Moura AM, de Sá AS, Rimes RR, Manochio JP, Arias-Carrión O, Mura G, Nardi AE, Machado S. Effects of chronic exercise on severity, quality of life and functionality in an elderly Parkinson's disease patient: case report. Clin Pract Epidemiol Ment Health 2014;10:126-8. [PMID: 25419223 DOI: 10.2174/1745017901410010126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
24 Wang Y, Ji X, Leak RK, Chen F, Cao G. Stem cell therapies in age-related neurodegenerative diseases and stroke. Ageing Res Rev 2017;34:39-50. [PMID: 27876573 DOI: 10.1016/j.arr.2016.11.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
25 Hu S, Tan J, Qin L, Lv L, Yan W, Zhang H, Tang B, Wang C. Molecular chaperones and Parkinson's disease. Neurobiol Dis 2021;160:105527. [PMID: 34626793 DOI: 10.1016/j.nbd.2021.105527] [Reference Citation Analysis]
26 Ferrer I, Garcia-Esparcia P, Carmona M, Carro E, Aronica E, Kovacs GG, Grison A, Gustincich S. Olfactory Receptors in Non-Chemosensory Organs: The Nervous System in Health and Disease. Front Aging Neurosci 2016;8:163. [PMID: 27458372 DOI: 10.3389/fnagi.2016.00163] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 8.3] [Reference Citation Analysis]
27 Sumi MP, Ghosh A. Hsp90 in Human Diseases: Molecular Mechanisms to Therapeutic Approaches. Cells 2022;11:976. [DOI: 10.3390/cells11060976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Sales TA, Prandi IG, Castro AA, Leal DHS, Cunha EFFD, Kuca K, Ramalho TC. Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments. Int J Mol Sci 2019;20:E1829. [PMID: 31013856 DOI: 10.3390/ijms20081829] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
29 Bertrand D, Lee CL, Flood D, Marger F, Donnelly-roberts D, Esbenshade TA. Therapeutic Potential of α 7 Nicotinic Acetylcholine Receptors. Pharmacol Rev 2015;67:1025-73. [DOI: 10.1124/pr.113.008581] [Cited by in Crossref: 87] [Cited by in F6Publishing: 85] [Article Influence: 12.4] [Reference Citation Analysis]
30 Ingram LA, Carroll VK, Butler AA, Brodie MA, Gandevia SC, Lord SR. Quantifying upper limb motor impairment in people with Parkinson's disease: a physiological profiling approach. PeerJ 2021;9:e10735. [PMID: 33604177 DOI: 10.7717/peerj.10735] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Vaidya B, Dhamija K, Guru P, Sharma SS. Parkinson's disease in women: Mechanisms underlying sex differences. Eur J Pharmacol 2021;895:173862. [PMID: 33450279 DOI: 10.1016/j.ejphar.2021.173862] [Reference Citation Analysis]
32 Ozaki Y, Yoshino Y, Yamazaki K, Ochi S, Iga JI, Nagai M, Nomoto M, Ueno SI. DRD2 methylation to differentiate dementia with Lewy bodies from Parkinson's disease. Acta Neurol Scand 2020;141:177-82. [PMID: 31659741 DOI: 10.1111/ane.13186] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
33 Tufail M, Hassan I. Influence of Consanguinity and Medication on the Development of Parkinson's Disease. Dement Geriatr Cogn Disord 2020;49:390-3. [PMID: 33105138 DOI: 10.1159/000509586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Iderberg H, Maslava N, Thompson AD, Bubser M, Niswender CM, Hopkins CR, Lindsley CW, Conn PJ, Jones CK, Cenci MA. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. Neuropharmacology 2015;95:121-9. [PMID: 25749357 DOI: 10.1016/j.neuropharm.2015.02.023] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
35 Litteljohn D, Rudyk C, Dwyer Z, Farmer K, Fortin T, Hayley S. The impact of murine LRRK2 G2019S transgene overexpression on acute responses to inflammatory challenge. Brain, Behavior, and Immunity 2018;67:246-56. [DOI: 10.1016/j.bbi.2017.09.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
36 Zhang J, Wang M, Zhao Y, Zhang Y, Gao Y, Zhang X, Yang G. Alpha-lipoic acid improved motor function in MPTP-induced Parkinsonian mice by reducing neuroinflammation in the nigral and spinal cord. Neurosci Lett 2022;781:136669. [PMID: 35490905 DOI: 10.1016/j.neulet.2022.136669] [Reference Citation Analysis]
37 Chen AY, Lü JM, Yao Q, Chen C. Entacapone is an Antioxidant More Potent than Vitamin C and Vitamin E for Scavenging of Hypochlorous Acid and Peroxynitrite, and the Inhibition of Oxidative Stress-Induced Cell Death. Med Sci Monit 2016;22:687-96. [PMID: 26927838 DOI: 10.12659/msm.896462] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
38 Eliewi AG, Al-garawi ZS, Al-kazzaz FF, Atia AJK. Multi target-directed imidazole derivatives for neurodegenerative diseases. J Phys : Conf Ser 2021;1853:012066. [DOI: 10.1088/1742-6596/1853/1/012066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
39 Vanhauwaert R, Verstreken P. Flies with Parkinson's disease. Exp Neurol 2015;274:42-51. [PMID: 25708988 DOI: 10.1016/j.expneurol.2015.02.020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
40 Lu L, Jia H, Gao G, Duan C, Ren J, Li Y, Yang H, Zhu L. Pink1 Regulates Tyrosine Hydroxylase Expression and Dopamine Synthesis. JAD 2018;63:1361-71. [DOI: 10.3233/jad-170832] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
41 Zhang J, Sun B, Yang J, Chen Z, Li Z, Zhang N, Li H, Shen L. Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models. Mol Med Rep 2022;25:91. [PMID: 35039876 DOI: 10.3892/mmr.2022.12607] [Reference Citation Analysis]
42 Huang K, Chang Y, Gau S, Tsai T, Lee C. Dose–Response Association of Metformin with Parkinson’s Disease Odds in Type 2 Diabetes Mellitus. Pharmaceutics 2022;14:946. [DOI: 10.3390/pharmaceutics14050946] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Fruhmann G, Seynnaeve D, Zheng J, Ven K, Molenberghs S, Wilms T, Liu B, Winderickx J, Franssens V. Yeast buddies helping to unravel the complexity of neurodegenerative disorders. Mechanisms of Ageing and Development 2017;161:288-305. [DOI: 10.1016/j.mad.2016.05.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
44 Kolagar TA, Farzaneh M, Nikkar N, Khoshnam SE. Human Pluripotent Stem Cells in Neurodegenerative Diseases: Potentials, Advances and Limitations. Curr Stem Cell Res Ther 2020;15:102-10. [PMID: 31441732 DOI: 10.2174/1574888X14666190823142911] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
45 Aras B, Seyyar GK, Fidan O, Colak E. The effect of Tai Chi on functional mobility, balance and falls in Parkinson's disease: A systematic review and meta-analysis of systematic reviews. Explore (NY) 2021:S1550-8307(21)00247-0. [PMID: 34952799 DOI: 10.1016/j.explore.2021.12.002] [Reference Citation Analysis]
46 Baumann A, Jorge-Finnigan A, Jung-Kc K, Sauter A, Horvath I, Morozova-Roche LA, Martinez A. Tyrosine Hydroxylase Binding to Phospholipid Membranes Prompts Its Amyloid Aggregation and Compromises Bilayer Integrity. Sci Rep 2016;6:39488. [PMID: 28004763 DOI: 10.1038/srep39488] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
47 Chedid J, Labrador-Garrido A, Zhong S, Gao J, Zhao Y, Perera G, Kim WS, Halliday GM, Dzamko N. A small molecule Toll-like receptor antagonist rescues α-synuclein fibril pathology. J Biol Chem 2022;:102260. [PMID: 35841928 DOI: 10.1016/j.jbc.2022.102260] [Reference Citation Analysis]
48 Guin D, Mishra MK, Talwar P, Rawat C, Kushwaha SS, Kukreti S, Kukreti R. A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease. BMC Med Genomics 2017;10:56. [PMID: 28927418 DOI: 10.1186/s12920-017-0291-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
49 Tay TL, Béchade C, D'Andrea I, St-Pierre MK, Henry MS, Roumier A, Tremblay ME. Microglia Gone Rogue: Impacts on Psychiatric Disorders across the Lifespan. Front Mol Neurosci 2017;10:421. [PMID: 29354029 DOI: 10.3389/fnmol.2017.00421] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 20.5] [Reference Citation Analysis]
50 Perez-Roca L, Adame-Castillo C, Campdelacreu J, Ispierto L, Vilas D, Rene R, Alvarez R, Gascon-Bayarri J, Serrano-Munoz MA, Ariza A, Beyer K. Glucocerebrosidase mRNA is Diminished in Brain of Lewy Body Diseases and Changes with Disease Progression in Blood. Aging Dis. 2018;9:208-219. [PMID: 29896411 DOI: 10.14336/ad.2017.0505] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
51 Lattari E, Costa SS, Campos C, de Oliveira AJ, Machado S, Maranhao Neto GA. Can transcranial direct current stimulation on the dorsolateral prefrontal cortex improves balance and functional mobility in Parkinson’s disease? Neuroscience Letters 2017;636:165-9. [DOI: 10.1016/j.neulet.2016.11.019] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 7.4] [Reference Citation Analysis]
52 Jellinger KA. Neuropathology of Nonmotor Symptoms of Parkinson's Disease. Int Rev Neurobiol 2017;133:13-62. [PMID: 28802920 DOI: 10.1016/bs.irn.2017.05.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
53 Alcacer C, Andreoli L, Sebastianutto I, Jakobsson J, Fieblinger T, Cenci MA. Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy. J Clin Invest 2017;127:720-34. [PMID: 28112685 DOI: 10.1172/JCI90132] [Cited by in Crossref: 64] [Cited by in F6Publishing: 31] [Article Influence: 12.8] [Reference Citation Analysis]
54 Rotermund C, Machetanz G, Fitzgerald JC. The Therapeutic Potential of Metformin in Neurodegenerative Diseases. Front Endocrinol (Lausanne) 2018;9:400. [PMID: 30072954 DOI: 10.3389/fendo.2018.00400] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 25.3] [Reference Citation Analysis]
55 Mahoney-Sánchez L, Bouchaoui H, Ayton S, Devos D, Duce JA, Devedjian JC. Ferroptosis and its potential role in the physiopathology of Parkinson's Disease. Prog Neurobiol 2021;196:101890. [PMID: 32726602 DOI: 10.1016/j.pneurobio.2020.101890] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
56 Ortega-Arellano HF, Jimenez-Del-Rio M, Velez-Pardo C. Minocycline protects, rescues and prevents knockdown transgenic parkin Drosophila against paraquat/iron toxicity: Implications for autosomic recessive juvenile parkinsonism. Neurotoxicology 2017;60:42-53. [PMID: 28284907 DOI: 10.1016/j.neuro.2017.03.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]